We are live on ! Find out more
KURA icon

Kura Oncology

183 hedge funds and large institutions have $531M invested in Kura Oncology in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 62 increasing their positions, 57 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

9% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 57

3% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 36

7% less call options, than puts

Call options by funds: $596K | Put options by funds: $640K

1% less funds holding

Funds holding: 185183 (-2)

1.74% less ownership

Funds ownership: 101.34%99.59% (-1.7%)

23% less capital invested

Capital invested by funds: $686M → $531M (-$155M)

Holders
183
Holders Change
-2
Holders Change %
-1.08%
% of All Funds
2.45%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
35
Increased
62
Reduced
57
Closed
36
Calls
$596K
Puts
$640K
Net Calls
-$44K
Net Calls Change
-$303K
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
26
Alethea Capital Management
Washington
$4.35M +$785K +100,735 +18%
Charles Schwab
27
Charles Schwab
California
$4.11M -$96.3K -12,354 -2%
SCM
28
Silverarc Capital Management
Massachusetts
$3.84M +$4.53M +581,369 New
Renaissance Technologies
29
Renaissance Technologies
New York
$3.52M -$508K -65,200 -11%
Walleye Capital
30
Walleye Capital
New York
$3.33M -$245K -31,461 -6%
Bank of America
31
Bank of America
North Carolina
$3.15M +$1.19M +152,383 +47%
DCM
32
DAFNA Capital Management
California
$3.06M +$117K +15,000 +3%
1CM
33
1492 Capital Management
Wisconsin
$2.84M +$679K +87,148 +25%
CS
34
Candriam SCA
Luxembourg
$2.79M
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$2.77M -$5.71M -732,207 -64%
Citadel Advisors
36
Citadel Advisors
Florida
$2.6M -$4.62M -592,710 -60%
Marshall Wace
37
Marshall Wace
United Kingdom
$2.59M -$4.34M -556,856 -59%
JP Morgan Chase
38
JP Morgan Chase
New York
$2.3M -$132K -16,904 -5%
SFM
39
Sphera Funds Management
Israel
$2.27M -$2.08M -266,565 -44%
Russell Investments Group
40
Russell Investments Group
United Kingdom
$2.24M +$313K +40,197 +13%
Acadian Asset Management
41
Acadian Asset Management
Massachusetts
$2.18M +$2.57M +330,421 New
Two Sigma Advisers
42
Two Sigma Advisers
New York
$1.84M +$284K +36,400 +15%
VC
43
Voss Capital
Texas
$1.65M -$195K -25,000 -9%
ECM
44
ExodusPoint Capital Management
New York
$1.59M -$440K -56,488 -19%
N
45
Nuveen
North Carolina
$1.56M +$423K +54,279 +30%
Bank of New York Mellon
46
Bank of New York Mellon
New York
$1.33M -$16.6K -2,129 -1%
RPAM
47
Rhenman & Partners Asset Management
Sweden
$1.29M -$931K -119,526 -38%
Barclays
48
Barclays
United Kingdom
$1.28M -$61.5K -7,890 -4%
JF
49
Jump Financial
Illinois
$1.27M -$368K -47,222 -20%
GCM
50
Graham Capital Management
Connecticut
$1.15M +$963K +123,610 +243%

KURA Hedge Fund Activity: Q1 2025 in Review

183 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2025, worth a combined $531M — down 23% from $686M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of KURA and 35 opened new positions — a net loss of 1 holder — while 57 trimmed existing stakes and 62 added.

The largest buyer was BVF Inc, adding an estimated $40.4M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $19.6M sold.

  • 183 institutional investors held Kura Oncology (KURA) as of Q1 2025, down from 185 in Q4 2024.
  • Funds reported $531M of Kura Oncology stock for Q1 2025, down 23% quarter-over-quarter.
  • 35 funds opened new Kura Oncology positions in Q1 2025 and 36 closed out, a net change of -1 holder.
  • The largest Kura Oncology buyer in Q1 2025 was BVF Inc, an estimated $40.4M added.
  • The largest Kura Oncology seller in Q1 2025 was Avoro Capital Advisors, an estimated $19.6M sold.

Based on aggregated 13F filings for Q1 2025.